Laboratories in the United States are facing a major regulatory landscape shift.
The U.S. Food and Drug Administration (FDA) has finalized a new rule ending its historical blanket enforcement discretion over laboratory developed tests (LDTs). What does this mean for labs going forward?
On this episode, Epstein Becker Green attorneys James Boiani, Rob Wanerman, and Megan Robertson lay out the new landscape, analyze existing and potential challenges, and identify key developments to watch for as this new regulatory era unfolds.
About the Diagnosing Health Care Podcast
The Diagnosing Health Care® podcast series examines the business opportunities and solutions that exist despite the high-stakes legal, policy, and regulatory issues that the health care industry faces.
Email Notifications
Podcast Apps
Never miss an episode! Subscribe to Diagnosing Health Care on your preferred platform:
Also on Audible | Deezer | Goodpods | iHeartRadio | PlayerFM | Pocket Casts | YouTube Music
People
- Member of the Firm
- Member of the Firm
- Member of the Firm
Services
- Academic and Clinical Research
- Drug and Medical Device Distribution
- FDA Inspections and Enforcement
- Health Care
- Health Care and Life Sciences Investigations and Enforcement
- Industry Research and Clinical Trials
- Life Sciences
- Life Sciences Due Diligence
- Regulatory Strategy, Product Development, and Product Approvals